Collectively, these findings identify p62 as a central regulator of tumor metabolism and immunity, suggesting that its context-dependent activity may dictate the balance between immune suppression and activation across cancers, and highlight two natural-product-derived PB1 inhibitors (ZINC70669789 and ZINC08877690) as promising candidates for therapeutic development. Here, SQSTM1 is linked to cancer.